AstraZeneca's shares are underperforming in the European market as well, due to weighing from banks and energy stocks. However, the pharmaceutical giant has not only been making strides in cancer research but has also contributed significantly to the fight against COVID-19. Despite setbacks, their portfolio of weight loss and GLP-1 drugs bolstered the overall performance leading to a rise in stock by 18% YTD.
AstraZeneca has maintained its targets and ratings despite these challenges. The company's leadership remains confident about the firm's powerful and differentiated approach to obesity treatment. Some growth has also been registered - Q2 saw an increase and short sellers consider the stock a good and cheap buy at present. Despite negative sentiments, several reasons like approvals for drugs and strong pipeline have resulted in the outperformance of the stock.
AstraZeneca Stocks News Analytics from Thu, 08 Feb 2024 08:00:00 GMT to Sat, 21 Sep 2024 15:19:48 GMT - Rating -3 - Innovation 4 - Information 7 - Rumor 2
